STOCK TITAN

[Form 4] Cardlytics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cardlytics, Inc. (CDLX) – Form 4 insider transaction filing

On 06/23/2025 the company granted its Chief Financial Officer, Alexis DeSieno, 40,000 restricted stock units (RSUs) and 15,000 performance stock units (PSUs). The awards were reported under transaction code “A” (grant) and carry a $0 exercise price, meaning they are issued at no cash cost to the executive.

The RSUs vest 50 % on 06/23/2026; the remaining 50 % vests in equal quarterly installments through 06/23/2027, subject to continued employment. The PSUs vest in specified percentages once undisclosed share-price hurdles are met, also contingent on employment. Following the grant, DeSieno beneficially owns 40,000 RSUs and 15,000 PSUs, all held directly.

Because the filing reflects equity compensation rather than an open-market purchase or sale, it does not alter immediate cash flows or signal a directional view on the stock. Nonetheless, the multi-year, performance-linked structure strengthens management alignment with long-term shareholder value while introducing potential future dilution of up to 55,000 shares.

Cardlytics, Inc. (CDLX) – Comunicazione interna Form 4

Il 23/06/2025 la società ha assegnato al suo Chief Financial Officer, Alexis DeSieno, 40.000 unità azionarie vincolate (RSU) e 15.000 unità azionarie legate a performance (PSU). Le assegnazioni sono state registrate con il codice transazione “A” (concessione) e hanno un prezzo di esercizio pari a $0, quindi sono concesse senza alcun costo in denaro per il dirigente.

Le RSU maturano per il 50% il 23/06/2026; il restante 50% matura in rate trimestrali uguali fino al 23/06/2027, subordinatamente alla permanenza in azienda. Le PSU maturano in percentuali specifiche al raggiungimento di obiettivi di prezzo azionario non divulgati, anch’esse condizionate all’impiego continuativo. Dopo la concessione, DeSieno detiene beneficiariamente 40.000 RSU e 15.000 PSU, tutte direttamente possedute.

Poiché la comunicazione riguarda una compensazione azionaria e non un acquisto o vendita sul mercato aperto, non modifica i flussi di cassa immediati né indica una posizione direzionale sul titolo. Tuttavia, la struttura pluriennale legata alla performance rafforza l’allineamento della direzione con il valore a lungo termine per gli azionisti, introducendo al contempo una possibile diluizione futura fino a 55.000 azioni.

Cardlytics, Inc. (CDLX) – Presentación del Formulario 4 de transacciones internas

El 23/06/2025, la empresa otorgó a su Director Financiero, Alexis DeSieno, 40,000 unidades de acciones restringidas (RSUs) y 15,000 unidades de acciones por desempeño (PSUs). Las concesiones se reportaron bajo el código de transacción “A” (concesión) y tienen un precio de ejercicio de $0, lo que significa que se otorgan sin costo en efectivo para el ejecutivo.

Las RSUs se consolidan en un 50% el 23/06/2026; el 50% restante se consolida en cuotas trimestrales iguales hasta el 23/06/2027, sujeto a la continuidad del empleo. Las PSUs se consolidan en porcentajes específicos una vez que se cumplen ciertos objetivos de precio por acción no divulgados, también condicionadas al empleo continuo. Tras la concesión, DeSieno posee beneficiosamente 40,000 RSUs y 15,000 PSUs, todas en propiedad directa.

Dado que la presentación refleja una compensación en acciones y no una compra o venta en el mercado abierto, no afecta los flujos de efectivo inmediatos ni señala una opinión direccional sobre la acción. No obstante, la estructura vinculada al desempeño a varios años fortalece la alineación de la gerencia con el valor a largo plazo para los accionistas, al tiempo que introduce una posible dilución futura de hasta 55,000 acciones.

Cardlytics, Inc. (CDLX) – 내부자 거래 신고서(Form 4)

2025년 6월 23일, 회사는 최고재무책임자(CFO) Alexis DeSieno에게 40,000개의 제한 주식 단위(RSU)15,000개의 성과 주식 단위(PSU)를 부여했습니다. 이 보상은 거래 코드 “A”(부여)로 보고되었으며, 행사 가격이 $0으로 임원에게 현금 비용 없이 발행되었습니다.

RSU는 2026년 6월 23일에 50%가 베스팅되며, 나머지 50%는 2027년 6월 23일까지 분기별로 동일하게 베스팅되며 계속 고용 조건이 붙습니다. PSU는 미공개된 주가 목표 달성 시 특정 비율로 베스팅되며, 역시 고용 상태가 유지되어야 합니다. 부여 후 DeSieno는 40,000 RSU와 15,000 PSU를 직접 보유하고 있습니다.

이 신고는 공개 시장에서의 매매가 아닌 주식 보상에 관한 것이므로 즉각적인 현금 흐름에 영향을 미치지 않으며 주가 방향성 신호도 아닙니다. 그럼에도 불구하고 다년간 성과 연동 구조는 경영진과 장기 주주 가치의 일치를 강화하며 최대 55,000주까지의 잠재적 희석 효과를 가져올 수 있습니다.

Cardlytics, Inc. (CDLX) – Déclaration de transaction d'initié Formulaire 4

Le 23/06/2025, la société a attribué à son Directeur Financier, Alexis DeSieno, 40 000 unités d'actions restreintes (RSU) et 15 000 unités d'actions de performance (PSU). Les attributions ont été déclarées sous le code de transaction « A » (attribution) avec un prix d'exercice de 0 $, ce qui signifie qu'elles sont émises sans coût en espèces pour le dirigeant.

Les RSU acquièrent 50 % de leur valeur le 23/06/2026 ; les 50 % restants sont acquis en versements trimestriels égaux jusqu'au 23/06/2027, sous réserve de la poursuite de l'emploi. Les PSU sont acquises selon des pourcentages spécifiques une fois que des seuils de prix d'action non divulgués sont atteints, également conditionnés à l'emploi continu. Après l'attribution, DeSieno détient directement 40 000 RSU et 15 000 PSU.

Étant donné que cette déclaration concerne une rémunération en actions et non un achat ou une vente sur le marché libre, elle n'affecte pas les flux de trésorerie immédiats ni ne signale une orientation sur le titre. Néanmoins, cette structure pluriannuelle liée à la performance renforce l'alignement de la direction avec la création de valeur à long terme pour les actionnaires, tout en introduisant une dilution potentielle future pouvant atteindre 55 000 actions.

Cardlytics, Inc. (CDLX) – Insider-Transaktion Meldung Form 4

Am 23.06.2025 gewährte das Unternehmen seinem Chief Financial Officer, Alexis DeSieno, 40.000 Restricted Stock Units (RSUs) und 15.000 Performance Stock Units (PSUs). Die Zuteilungen wurden unter dem Transaktionscode „A“ (Gewährung) gemeldet und haben einen Ausübungspreis von 0 $, was bedeutet, dass sie dem Manager ohne Baraufwand gewährt wurden.

Die RSUs werden zu 50 % am 23.06.2026 fällig; die restlichen 50 % werden in gleichen vierteljährlichen Raten bis zum 23.06.2027 fällig, vorbehaltlich einer fortdauernden Anstellung. Die PSUs werden in bestimmten Prozentsätzen fällig, sobald nicht offengelegte Kursziele erreicht sind, ebenfalls abhängig von der Beschäftigung. Nach der Gewährung hält DeSieno wirtschaftlich 40.000 RSUs und 15.000 PSUs, alle direkt gehalten.

Da die Meldung eine Aktienvergütung und keinen Kauf oder Verkauf am offenen Markt darstellt, ändert sie die unmittelbaren Cashflows nicht und signalisiert keine Richtungsentscheidung für die Aktie. Dennoch stärkt die mehrjährige, leistungsabhängige Struktur die Ausrichtung des Managements auf den langfristigen Shareholder Value und bringt eine potenzielle zukünftige Verwässerung von bis zu 55.000 Aktien mit sich.

Positive
  • Long-term incentive alignment: Multi-year RSU and performance-based PSU structure ties CFO compensation to shareholder value.
  • Retention mechanism: Vesting through 2027 encourages executive stability during strategic execution.
Negative
  • Share dilution risk: Full vesting could add up to 55,000 new shares to the float.

Insights

TL;DR: Routine equity grant aligns CFO with shareholders; neutral market impact.

The Form 4 discloses standard incentive awards—40,000 RSUs and 15,000 PSUs—to newly appointed CFO Alexis DeSieno. Transaction code “A” indicates a compensatory grant, not a purchase or sale, so no price signal exists. Vesting stretches to 2027 and ties PSU conversion to share-price targets, encouraging retention and performance. From a governance lens, the grant size is modest and consistent with typical executive packages in mid-cap fintech, creating limited dilution. Absent sales, purchases or material option exercises, the filing is neutral for investors.

Cardlytics, Inc. (CDLX) – Comunicazione interna Form 4

Il 23/06/2025 la società ha assegnato al suo Chief Financial Officer, Alexis DeSieno, 40.000 unità azionarie vincolate (RSU) e 15.000 unità azionarie legate a performance (PSU). Le assegnazioni sono state registrate con il codice transazione “A” (concessione) e hanno un prezzo di esercizio pari a $0, quindi sono concesse senza alcun costo in denaro per il dirigente.

Le RSU maturano per il 50% il 23/06/2026; il restante 50% matura in rate trimestrali uguali fino al 23/06/2027, subordinatamente alla permanenza in azienda. Le PSU maturano in percentuali specifiche al raggiungimento di obiettivi di prezzo azionario non divulgati, anch’esse condizionate all’impiego continuativo. Dopo la concessione, DeSieno detiene beneficiariamente 40.000 RSU e 15.000 PSU, tutte direttamente possedute.

Poiché la comunicazione riguarda una compensazione azionaria e non un acquisto o vendita sul mercato aperto, non modifica i flussi di cassa immediati né indica una posizione direzionale sul titolo. Tuttavia, la struttura pluriennale legata alla performance rafforza l’allineamento della direzione con il valore a lungo termine per gli azionisti, introducendo al contempo una possibile diluizione futura fino a 55.000 azioni.

Cardlytics, Inc. (CDLX) – Presentación del Formulario 4 de transacciones internas

El 23/06/2025, la empresa otorgó a su Director Financiero, Alexis DeSieno, 40,000 unidades de acciones restringidas (RSUs) y 15,000 unidades de acciones por desempeño (PSUs). Las concesiones se reportaron bajo el código de transacción “A” (concesión) y tienen un precio de ejercicio de $0, lo que significa que se otorgan sin costo en efectivo para el ejecutivo.

Las RSUs se consolidan en un 50% el 23/06/2026; el 50% restante se consolida en cuotas trimestrales iguales hasta el 23/06/2027, sujeto a la continuidad del empleo. Las PSUs se consolidan en porcentajes específicos una vez que se cumplen ciertos objetivos de precio por acción no divulgados, también condicionadas al empleo continuo. Tras la concesión, DeSieno posee beneficiosamente 40,000 RSUs y 15,000 PSUs, todas en propiedad directa.

Dado que la presentación refleja una compensación en acciones y no una compra o venta en el mercado abierto, no afecta los flujos de efectivo inmediatos ni señala una opinión direccional sobre la acción. No obstante, la estructura vinculada al desempeño a varios años fortalece la alineación de la gerencia con el valor a largo plazo para los accionistas, al tiempo que introduce una posible dilución futura de hasta 55,000 acciones.

Cardlytics, Inc. (CDLX) – 내부자 거래 신고서(Form 4)

2025년 6월 23일, 회사는 최고재무책임자(CFO) Alexis DeSieno에게 40,000개의 제한 주식 단위(RSU)15,000개의 성과 주식 단위(PSU)를 부여했습니다. 이 보상은 거래 코드 “A”(부여)로 보고되었으며, 행사 가격이 $0으로 임원에게 현금 비용 없이 발행되었습니다.

RSU는 2026년 6월 23일에 50%가 베스팅되며, 나머지 50%는 2027년 6월 23일까지 분기별로 동일하게 베스팅되며 계속 고용 조건이 붙습니다. PSU는 미공개된 주가 목표 달성 시 특정 비율로 베스팅되며, 역시 고용 상태가 유지되어야 합니다. 부여 후 DeSieno는 40,000 RSU와 15,000 PSU를 직접 보유하고 있습니다.

이 신고는 공개 시장에서의 매매가 아닌 주식 보상에 관한 것이므로 즉각적인 현금 흐름에 영향을 미치지 않으며 주가 방향성 신호도 아닙니다. 그럼에도 불구하고 다년간 성과 연동 구조는 경영진과 장기 주주 가치의 일치를 강화하며 최대 55,000주까지의 잠재적 희석 효과를 가져올 수 있습니다.

Cardlytics, Inc. (CDLX) – Déclaration de transaction d'initié Formulaire 4

Le 23/06/2025, la société a attribué à son Directeur Financier, Alexis DeSieno, 40 000 unités d'actions restreintes (RSU) et 15 000 unités d'actions de performance (PSU). Les attributions ont été déclarées sous le code de transaction « A » (attribution) avec un prix d'exercice de 0 $, ce qui signifie qu'elles sont émises sans coût en espèces pour le dirigeant.

Les RSU acquièrent 50 % de leur valeur le 23/06/2026 ; les 50 % restants sont acquis en versements trimestriels égaux jusqu'au 23/06/2027, sous réserve de la poursuite de l'emploi. Les PSU sont acquises selon des pourcentages spécifiques une fois que des seuils de prix d'action non divulgués sont atteints, également conditionnés à l'emploi continu. Après l'attribution, DeSieno détient directement 40 000 RSU et 15 000 PSU.

Étant donné que cette déclaration concerne une rémunération en actions et non un achat ou une vente sur le marché libre, elle n'affecte pas les flux de trésorerie immédiats ni ne signale une orientation sur le titre. Néanmoins, cette structure pluriannuelle liée à la performance renforce l'alignement de la direction avec la création de valeur à long terme pour les actionnaires, tout en introduisant une dilution potentielle future pouvant atteindre 55 000 actions.

Cardlytics, Inc. (CDLX) – Insider-Transaktion Meldung Form 4

Am 23.06.2025 gewährte das Unternehmen seinem Chief Financial Officer, Alexis DeSieno, 40.000 Restricted Stock Units (RSUs) und 15.000 Performance Stock Units (PSUs). Die Zuteilungen wurden unter dem Transaktionscode „A“ (Gewährung) gemeldet und haben einen Ausübungspreis von 0 $, was bedeutet, dass sie dem Manager ohne Baraufwand gewährt wurden.

Die RSUs werden zu 50 % am 23.06.2026 fällig; die restlichen 50 % werden in gleichen vierteljährlichen Raten bis zum 23.06.2027 fällig, vorbehaltlich einer fortdauernden Anstellung. Die PSUs werden in bestimmten Prozentsätzen fällig, sobald nicht offengelegte Kursziele erreicht sind, ebenfalls abhängig von der Beschäftigung. Nach der Gewährung hält DeSieno wirtschaftlich 40.000 RSUs und 15.000 PSUs, alle direkt gehalten.

Da die Meldung eine Aktienvergütung und keinen Kauf oder Verkauf am offenen Markt darstellt, ändert sie die unmittelbaren Cashflows nicht und signalisiert keine Richtungsentscheidung für die Aktie. Dennoch stärkt die mehrjährige, leistungsabhängige Struktur die Ausrichtung des Managements auf den langfristigen Shareholder Value und bringt eine potenzielle zukünftige Verwässerung von bis zu 55.000 Aktien mit sich.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DeSieno Alexis

(Last) (First) (Middle)
675 PONCE DE LEON AVE. NE
SUITE 4100

(Street)
ATLANTA GA 30308

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cardlytics, Inc. [ CDLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 06/23/2025 A 40,000 (2) (2) Common Stock 40,000 $0 40,000 D
Performance Stock Unit (3) 06/23/2025 A 15,000 (4) (4) Common Stock 15,000 $0 15,000 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. 50% of the shares underlying the RSU award will vest on June 23, 2026, with the remaining 50% vesting in equal amounts quarterly over a one-year period through June 23, 2027, provided that the Reporting Person remains employed by the Issuer on such vesting dates.
3. Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.
4. The PSU vests in specified percentages upon achievement of specified price per share targets, provided that the Reporting Person remains employed by the Issuer on such vesting dates.
Remarks:
/s/ Nick Lynton, Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RSUs were granted to Cardlytics CFO Alexis DeSieno?

The Form 4 shows a grant of 40,000 restricted stock units on 06/23/2025.

What is the vesting schedule for the RSUs granted by CDLX?

50 % vests on 06/23/2026; the remaining 50 % vests quarterly through 06/23/2027, subject to continued employment.

How many performance stock units were issued and what triggers vesting?

The CFO received 15,000 PSUs that vest in specified percentages once certain share-price targets are achieved and employment continues.

Does the Form 4 report any insider purchase or sale of CDLX common stock?

No. The filing only reports compensatory grants (transaction code “A”), with no open-market purchases or sales.

When was the Form 4 for Cardlytics filed?

The document was electronically signed on 06/25/2025 and covers transactions dated 06/23/2025.

What transaction code appears in the Cardlytics Form 4?

The filing uses transaction code “A”, indicating an equity award under an employee compensation plan.
Cardlytics

NASDAQ:CDLX

CDLX Rankings

CDLX Latest News

CDLX Latest SEC Filings

CDLX Stock Data

87.15M
51.08M
5.12%
57.68%
17.68%
Advertising Agencies
Services-computer Programming, Data Processing, Etc.
Link
United States
ATLANTA